Nipocalimab in Moderate to Severe Sjogren's Disease
- Conditions
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 600
- Registration Number
- NCT06741969
- Locations
- πΊπΈ
Inland Rheumatology Clinical Trials Inc., Upland, California, United States
πΊπΈClinical Investigation Specialists - Clinic of Robert Hozman, Skokie, Illinois, United States
πΊπΈAltoona Center For Clinical Research, Duncansville, Pennsylvania, United States
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 365
- Registration Number
- NCT06667076
- Locations
- πΊπΈ
Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
πΊπΈProvidence Medical Foundation, Santa Rosa, California, United States
πΊπΈHope and Healing Cancer Services, Hinsdale, Illinois, United States
A Study of JNJ-89402638 for Metastatic Colorectal Cancer
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT06663319
- Locations
- πΊπΈ
Florida Cancer Specialists, Sarasota, Florida, United States
πΊπΈStart Midwest, Grand Rapids, Michigan, United States
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Conditions
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 196
- Registration Number
- NCT06663332
- Locations
- πͺπΈ
Hosp. Clinico Univ. de Santiago, Santiago de Compostela, Spain
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1000
- Registration Number
- NCT06662786
- Locations
- π²πΎ
Hospital Pulau Pinang, Georgetown, Malaysia
π²πΎHospital Umum Sarawak, Kuching, Malaysia
π²πΎHospital Raja Permaisuri Bainun, Ipoh, Malaysia
A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT06660563
- Locations
- π¦πΊ
St Vincents Hospital Melbourne, Fitzroy, Australia
π¦πΊMacquarie University Hospital, North Ryde, Australia
πͺπΈHosp. Clinic de Barcelona, Barcelona, Spain
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT06651229
A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)
- Conditions
- Interventions
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 42
- Registration Number
- NCT06646289
- Locations
- πΊπΈ
University of Michigan Kellogg Eye Center, Ann Arbor, Michigan, United States
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
- Conditions
- Interventions
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 311
- Registration Number
- NCT06635148
- Locations
- πΊπΈ
Retina Consultants of Orange County, Fullerton, California, United States
πΊπΈRetina Specialty Institute, Pensacola, Florida, United States
πΊπΈMarietta Eye Clinic, Marietta, Georgia, United States
A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure
- Conditions
- Interventions
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 660
- Registration Number
- NCT06635135
- Locations
- πΊπΈ
Laureate Institute for Brain Research, Tulsa, Oklahoma, United States
πΊπΈInSite Clinical Research LLC, DeSoto, Texas, United States
πΊπΈEarle Research, Friendswood, Texas, United States